http://www.streetinsider.com Latest StreetInsider.com News Articles en-us Copyright 2026, StreetInsider.com rss@streetinsider.com (SI RSS) rss@streetinsider.com (SI RSS) Fri, 13 Mar 2026 17:17:00 -0400 http://blogs.law.harvard.edu/tech/rss http://www.streetinsider.com/images/rss_logo.gif http://www.streetinsider.com 143 28 0 1 2 3 21 22 23 Saturday Sunday http://www.streetinsider.com/SEC+Filings/Form++424B5++++++60+DEGREES+PHARMACEUTICA+++++++++++++/26160618.html si-local-file:///var/storage/secattach/20260313/26160618.html http://www.streetinsider.com/SEC+Filings/Form++424B5++++++60+DEGREES+PHARMACEUTICA+++++++++++++/26160618.html Fri, 13 Mar 2026 17:17:00 -0400 O.58280676 SXTP http://www.streetinsider.com/SEC+Filings/Form++424B5++++++60+DEGREES+PHARMACEUTICA+++++++++++++/26160618.html si-local-file:///var/storage/secattach/20260313/26160618.html http://www.streetinsider.com/SEC+Filings/Form++424B5++++++60+DEGREES+PHARMACEUTICA+++++++++++++/26160618.html Fri, 13 Mar 2026 17:17:00 -0400 O.58280676 SXTP http://www.streetinsider.com/SEC+Filings/Form++8-K++++++++60+DEGREES+PHARMACEUTICA++For%3A+Mar+13/26160598.html si-local-file:///var/storage/secattach/20260313/26160598.html http://www.streetinsider.com/SEC+Filings/Form++8-K++++++++60+DEGREES+PHARMACEUTICA++For%3A+Mar+13/26160598.html Fri, 13 Mar 2026 17:15:00 -0400 O.58280676 SXTP http://www.streetinsider.com/SEC+Filings/Form++8-K++++++++60+DEGREES+PHARMACEUTICA++For%3A+Mar+13/26160598.html si-local-file:///var/storage/secattach/20260313/26160598.html http://www.streetinsider.com/SEC+Filings/Form++8-K++++++++60+DEGREES+PHARMACEUTICA++For%3A+Mar+13/26160598.html Fri, 13 Mar 2026 17:15:00 -0400 O.58280676 SXTP http://www.streetinsider.com/SEC+Filings/Form++8-K++++++++60+DEGREES+PHARMACEUTICA++For%3A+Mar+12/26153899.html si-local-file:///var/storage/secattach/20260312/26153899.html http://www.streetinsider.com/SEC+Filings/Form++8-K++++++++60+DEGREES+PHARMACEUTICA++For%3A+Mar+12/26153899.html Thu, 12 Mar 2026 16:37:00 -0400 O.58280676 SXTP http://www.streetinsider.com/SEC+Filings/Form++8-K++++++++60+DEGREES+PHARMACEUTICA++For%3A+Mar+12/26153899.html si-local-file:///var/storage/secattach/20260312/26153899.html http://www.streetinsider.com/SEC+Filings/Form++8-K++++++++60+DEGREES+PHARMACEUTICA++For%3A+Mar+12/26153899.html Thu, 12 Mar 2026 16:37:00 -0400 O.58280676 SXTP http://www.streetinsider.com/SEC+Filings/Form++424B5++++++60+DEGREES+PHARMACEUTICA+++++++++++++/26147288.html si-local-file:///var/storage/secattach/20260311/26147288.html http://www.streetinsider.com/SEC+Filings/Form++424B5++++++60+DEGREES+PHARMACEUTICA+++++++++++++/26147288.html Wed, 11 Mar 2026 17:25:00 -0400 O.58280676 SXTP http://www.streetinsider.com/SEC+Filings/Form++424B5++++++60+DEGREES+PHARMACEUTICA+++++++++++++/26147288.html si-local-file:///var/storage/secattach/20260311/26147288.html http://www.streetinsider.com/SEC+Filings/Form++424B5++++++60+DEGREES+PHARMACEUTICA+++++++++++++/26147288.html Wed, 11 Mar 2026 17:25:00 -0400 O.58280676 SXTP http://www.streetinsider.com/Corporate+News/60+Degrees+Pharmaceuticals+reports+babesiosis+cures+in+small+trial/26142602.html <p>60 Degrees Pharmaceuticals Inc. (NASDAQ: SXTP) announced that three patients with relapsing babesiosis were cured after treatment with tafenoquine in an expanded use clinical trial.</p><p>The Washington-based pharmaceutical company conducted an open-label, multi-site study evaluating tafenoquine combined with atovaquone and other antimalarials in immunosuppressed patients who had previously failed conventional treatments. All three enrolled patients achieved cure status, as determined by negative RNA amplification tests following treatment completion.</p><p>The trial builds on a 2024 Yale School of Public Health study published in Clinical Infectious Diseases, which reported a 100% treatment success rate in four of five patients when tafenoquine was combined with http://www.streetinsider.com/Corporate+News/60+Degrees+Pharmaceuticals+reports+babesiosis+cures+in+small+trial/26142602.html Wed, 11 Mar 2026 07:24:48 -0400 SXTP SXTPW http://www.streetinsider.com/Corporate+News/60+Degrees+Pharmaceuticals+reports+babesiosis+cures+in+small+trial/26142602.html <p>60 Degrees Pharmaceuticals Inc. (NASDAQ: SXTP) announced that three patients with relapsing babesiosis were cured after treatment with tafenoquine in an expanded use clinical trial.</p><p>The Washington-based pharmaceutical company conducted an open-label, multi-site study evaluating tafenoquine combined with atovaquone and other antimalarials in immunosuppressed patients who had previously failed conventional treatments. All three enrolled patients achieved cure status, as determined by negative RNA amplification tests following treatment completion.</p><p>The trial builds on a 2024 Yale School of Public Health study published in Clinical Infectious Diseases, which reported a 100% treatment success rate in four of five patients when tafenoquine was combined with http://www.streetinsider.com/Corporate+News/60+Degrees+Pharmaceuticals+reports+babesiosis+cures+in+small+trial/26142602.html Wed, 11 Mar 2026 07:24:48 -0400 SXTP SXTPW http://www.streetinsider.com/FDA/60+Degrees+Pharmaceuticals+reports+babesiosis+cures+in+small+trial/26142602.html <p>60 Degrees Pharmaceuticals Inc. (NASDAQ: SXTP) announced that three patients with relapsing babesiosis were cured after treatment with tafenoquine in an expanded use clinical trial.</p><p>The Washington-based pharmaceutical company conducted an open-label, multi-site study evaluating tafenoquine combined with atovaquone and other antimalarials in immunosuppressed patients who had previously failed conventional treatments. All three enrolled patients achieved cure status, as determined by negative RNA amplification tests following treatment completion.</p><p>The trial builds on a 2024 Yale School of Public Health study published in Clinical Infectious Diseases, which reported a 100% treatment success rate in four of five patients when tafenoquine was combined with http://www.streetinsider.com/FDA/60+Degrees+Pharmaceuticals+reports+babesiosis+cures+in+small+trial/26142602.html Wed, 11 Mar 2026 07:24:48 -0400 SXTP SXTPW http://www.streetinsider.com/FDA/60+Degrees+Pharmaceuticals+reports+babesiosis+cures+in+small+trial/26142602.html <p>60 Degrees Pharmaceuticals Inc. (NASDAQ: SXTP) announced that three patients with relapsing babesiosis were cured after treatment with tafenoquine in an expanded use clinical trial.</p><p>The Washington-based pharmaceutical company conducted an open-label, multi-site study evaluating tafenoquine combined with atovaquone and other antimalarials in immunosuppressed patients who had previously failed conventional treatments. All three enrolled patients achieved cure status, as determined by negative RNA amplification tests following treatment completion.</p><p>The trial builds on a 2024 Yale School of Public Health study published in Clinical Infectious Diseases, which reported a 100% treatment success rate in four of five patients when tafenoquine was combined with http://www.streetinsider.com/FDA/60+Degrees+Pharmaceuticals+reports+babesiosis+cures+in+small+trial/26142602.html Wed, 11 Mar 2026 07:24:48 -0400 SXTP SXTPW http://www.streetinsider.com/Hot+FDA+News/60+Degrees+Pharmaceuticals+reports+babesiosis+cures+in+small+trial/26142602.html <p>60 Degrees Pharmaceuticals Inc. (NASDAQ: SXTP) announced that three patients with relapsing babesiosis were cured after treatment with tafenoquine in an expanded use clinical trial.</p><p>The Washington-based pharmaceutical company conducted an open-label, multi-site study evaluating tafenoquine combined with atovaquone and other antimalarials in immunosuppressed patients who had previously failed conventional treatments. All three enrolled patients achieved cure status, as determined by negative RNA amplification tests following treatment completion.</p><p>The trial builds on a 2024 Yale School of Public Health study published in Clinical Infectious Diseases, which reported a 100% treatment success rate in four of five patients when tafenoquine was combined with http://www.streetinsider.com/Hot+FDA+News/60+Degrees+Pharmaceuticals+reports+babesiosis+cures+in+small+trial/26142602.html Wed, 11 Mar 2026 07:24:48 -0400 SXTP SXTPW http://www.streetinsider.com/Hot+FDA+News/60+Degrees+Pharmaceuticals+reports+babesiosis+cures+in+small+trial/26142602.html <p>60 Degrees Pharmaceuticals Inc. (NASDAQ: SXTP) announced that three patients with relapsing babesiosis were cured after treatment with tafenoquine in an expanded use clinical trial.</p><p>The Washington-based pharmaceutical company conducted an open-label, multi-site study evaluating tafenoquine combined with atovaquone and other antimalarials in immunosuppressed patients who had previously failed conventional treatments. All three enrolled patients achieved cure status, as determined by negative RNA amplification tests following treatment completion.</p><p>The trial builds on a 2024 Yale School of Public Health study published in Clinical Infectious Diseases, which reported a 100% treatment success rate in four of five patients when tafenoquine was combined with http://www.streetinsider.com/Hot+FDA+News/60+Degrees+Pharmaceuticals+reports+babesiosis+cures+in+small+trial/26142602.html Wed, 11 Mar 2026 07:24:48 -0400 SXTP SXTPW http://www.streetinsider.com/Press+Releases/60+Degrees+Pharmaceuticals+Announces+All+Patients+Cured+of+Babesiosis+After+Tafenoquine+Treatment+in+Expanded+Use+Clinical+Trial/26142599.html <ul><li>All three patients enrolled in study have been cured, confirming high cure rate of <strong>tafenoquine</strong> in immunosuppressed patients, as reported by Yale in a 2024 publication</li><li>Company calls for existing babesiosis treatment guidelines to be reviewed in light of the new data</li></ul> <p>WASHINGTON, March 11, 2026 (GLOBE NEWSWIRE) -- <a target="_blank" href="https://www.globenewswire.com/Tracker?data=Xh3W3ckQCJSwUsxtLRhEbKHxgPNlNKSp2QaVxFX-36w4b2c7EqcmudQ7Wtel6waeC2-_XF86mo579UbrGzCwHt8LznYmPsahGyfemenDObigbVN7m9z7OId9maVJUmXDb5Na9ylOd-Y-d8MQLXGeLQ==" rel="nofollow" target="_blank">60 Degrees Pharmaceuticals, Inc.</a> (NASDAQ: SXTP; SXTPW) (“60 Degrees” or the “Company”), a pharmaceutical company focused on developing new medicines for vector-borne disease, today announced that three of three enrolled patients have been cured of babesiosis after completing the<strong> tafenoquine</strong> regimen in the Company’s trial of relapsing http://www.streetinsider.com/Press+Releases/60+Degrees+Pharmaceuticals+Announces+All+Patients+Cured+of+Babesiosis+After+Tafenoquine+Treatment+in+Expanded+Use+Clinical+Trial/26142599.html Wed, 11 Mar 2026 07:24:00 -0400 A.06822034 A.14320728 O.20026344 O.20250741 O.58280676 SXTP SXTPW http://www.streetinsider.com/Press+Releases/60+Degrees+Pharmaceuticals+Announces+All+Patients+Cured+of+Babesiosis+After+Tafenoquine+Treatment+in+Expanded+Use+Clinical+Trial/26142599.html <ul><li>All three patients enrolled in study have been cured, confirming high cure rate of <strong>tafenoquine</strong> in immunosuppressed patients, as reported by Yale in a 2024 publication</li><li>Company calls for existing babesiosis treatment guidelines to be reviewed in light of the new data</li></ul> <p>WASHINGTON, March 11, 2026 (GLOBE NEWSWIRE) -- <a target="_blank" href="https://www.globenewswire.com/Tracker?data=Xh3W3ckQCJSwUsxtLRhEbKHxgPNlNKSp2QaVxFX-36w4b2c7EqcmudQ7Wtel6waeC2-_XF86mo579UbrGzCwHt8LznYmPsahGyfemenDObigbVN7m9z7OId9maVJUmXDb5Na9ylOd-Y-d8MQLXGeLQ==" rel="nofollow" target="_blank">60 Degrees Pharmaceuticals, Inc.</a> (NASDAQ: SXTP; SXTPW) (“60 Degrees” or the “Company”), a pharmaceutical company focused on developing new medicines for vector-borne disease, today announced that three of three enrolled patients have been cured of babesiosis after completing the<strong> tafenoquine</strong> regimen in the Company’s trial of relapsing http://www.streetinsider.com/Press+Releases/60+Degrees+Pharmaceuticals+Announces+All+Patients+Cured+of+Babesiosis+After+Tafenoquine+Treatment+in+Expanded+Use+Clinical+Trial/26142599.html Wed, 11 Mar 2026 07:24:00 -0400 A.06822034 A.14320728 O.20026344 O.20250741 O.58280676 SXTP SXTPW http://www.streetinsider.com/Press+Releases/60+Degrees+Pharmaceuticals+Announces+All+Patients+Cured+of+Babesiosis+After+Tafenoquine+Treatment+in+Expanded+Use+Clinical+Trial/26142599.html <ul><li>All three patients enrolled in study have been cured, confirming high cure rate of <strong>tafenoquine</strong> in immunosuppressed patients, as reported by Yale in a 2024 publication</li><li>Company calls for existing babesiosis treatment guidelines to be reviewed in light of the new data</li></ul> <p>WASHINGTON, March 11, 2026 (GLOBE NEWSWIRE) -- <a target="_blank" href="https://www.globenewswire.com/Tracker?data=Xh3W3ckQCJSwUsxtLRhEbKHxgPNlNKSp2QaVxFX-36w4b2c7EqcmudQ7Wtel6waeC2-_XF86mo579UbrGzCwHt8LznYmPsahGyfemenDObigbVN7m9z7OId9maVJUmXDb5Na9ylOd-Y-d8MQLXGeLQ==" rel="nofollow" target="_blank">60 Degrees Pharmaceuticals, Inc.</a> (NASDAQ: SXTP; SXTPW) (“60 Degrees” or the “Company”), a pharmaceutical company focused on developing new medicines for vector-borne disease, today announced that three of three enrolled patients have been cured of babesiosis after completing the<strong> tafenoquine</strong> regimen in the Company’s trial of relapsing http://www.streetinsider.com/Press+Releases/60+Degrees+Pharmaceuticals+Announces+All+Patients+Cured+of+Babesiosis+After+Tafenoquine+Treatment+in+Expanded+Use+Clinical+Trial/26142599.html Wed, 11 Mar 2026 07:24:00 -0400 A.06822034 A.14320728 O.20026344 O.20250741 O.58280676 SXTP SXTPW http://www.streetinsider.com/Press+Releases/60+Degrees+Pharmaceuticals+Announces+All+Patients+Cured+of+Babesiosis+After+Tafenoquine+Treatment+in+Expanded+Use+Clinical+Trial/26142599.html <ul><li>All three patients enrolled in study have been cured, confirming high cure rate of <strong>tafenoquine</strong> in immunosuppressed patients, as reported by Yale in a 2024 publication</li><li>Company calls for existing babesiosis treatment guidelines to be reviewed in light of the new data</li></ul> <p>WASHINGTON, March 11, 2026 (GLOBE NEWSWIRE) -- <a target="_blank" href="https://www.globenewswire.com/Tracker?data=Xh3W3ckQCJSwUsxtLRhEbKHxgPNlNKSp2QaVxFX-36w4b2c7EqcmudQ7Wtel6waeC2-_XF86mo579UbrGzCwHt8LznYmPsahGyfemenDObigbVN7m9z7OId9maVJUmXDb5Na9ylOd-Y-d8MQLXGeLQ==" rel="nofollow" target="_blank">60 Degrees Pharmaceuticals, Inc.</a> (NASDAQ: SXTP; SXTPW) (“60 Degrees” or the “Company”), a pharmaceutical company focused on developing new medicines for vector-borne disease, today announced that three of three enrolled patients have been cured of babesiosis after completing the<strong> tafenoquine</strong> regimen in the Company’s trial of relapsing http://www.streetinsider.com/Press+Releases/60+Degrees+Pharmaceuticals+Announces+All+Patients+Cured+of+Babesiosis+After+Tafenoquine+Treatment+in+Expanded+Use+Clinical+Trial/26142599.html Wed, 11 Mar 2026 07:24:00 -0400 A.06822034 A.14320728 O.20026344 O.20250741 O.58280676 SXTP SXTPW http://www.streetinsider.com/Press+Releases/60+Degrees+Pharmaceuticals+Announces+All+Patients+Cured+of+Babesiosis+After+Tafenoquine+Treatment+in+Expanded+Use+Clinical+Trial/26142599.html <ul><li>All three patients enrolled in study have been cured, confirming high cure rate of <strong>tafenoquine</strong> in immunosuppressed patients, as reported by Yale in a 2024 publication</li><li>Company calls for existing babesiosis treatment guidelines to be reviewed in light of the new data</li></ul> <p>WASHINGTON, March 11, 2026 (GLOBE NEWSWIRE) -- <a target="_blank" href="https://www.globenewswire.com/Tracker?data=Xh3W3ckQCJSwUsxtLRhEbKHxgPNlNKSp2QaVxFX-36w4b2c7EqcmudQ7Wtel6waeC2-_XF86mo579UbrGzCwHt8LznYmPsahGyfemenDObigbVN7m9z7OId9maVJUmXDb5Na9ylOd-Y-d8MQLXGeLQ==" rel="nofollow" target="_blank">60 Degrees Pharmaceuticals, Inc.</a> (NASDAQ: SXTP; SXTPW) (“60 Degrees” or the “Company”), a pharmaceutical company focused on developing new medicines for vector-borne disease, today announced that three of three enrolled patients have been cured of babesiosis after completing the<strong> tafenoquine</strong> regimen in the Company’s trial of relapsing http://www.streetinsider.com/Press+Releases/60+Degrees+Pharmaceuticals+Announces+All+Patients+Cured+of+Babesiosis+After+Tafenoquine+Treatment+in+Expanded+Use+Clinical+Trial/26142599.html Wed, 11 Mar 2026 07:24:00 -0400 A.06822034 A.14320728 O.20026344 O.20250741 O.58280676 SXTP SXTPW http://www.streetinsider.com/Press+Releases/60+Degrees+Pharmaceuticals+Announces+All+Patients+Cured+of+Babesiosis+After+Tafenoquine+Treatment+in+Expanded+Use+Clinical+Trial/26142599.html <ul><li>All three patients enrolled in study have been cured, confirming high cure rate of <strong>tafenoquine</strong> in immunosuppressed patients, as reported by Yale in a 2024 publication</li><li>Company calls for existing babesiosis treatment guidelines to be reviewed in light of the new data</li></ul> <p>WASHINGTON, March 11, 2026 (GLOBE NEWSWIRE) -- <a target="_blank" href="https://www.globenewswire.com/Tracker?data=Xh3W3ckQCJSwUsxtLRhEbKHxgPNlNKSp2QaVxFX-36w4b2c7EqcmudQ7Wtel6waeC2-_XF86mo579UbrGzCwHt8LznYmPsahGyfemenDObigbVN7m9z7OId9maVJUmXDb5Na9ylOd-Y-d8MQLXGeLQ==" rel="nofollow" target="_blank">60 Degrees Pharmaceuticals, Inc.</a> (NASDAQ: SXTP; SXTPW) (“60 Degrees” or the “Company”), a pharmaceutical company focused on developing new medicines for vector-borne disease, today announced that three of three enrolled patients have been cured of babesiosis after completing the<strong> tafenoquine</strong> regimen in the Company’s trial of relapsing http://www.streetinsider.com/Press+Releases/60+Degrees+Pharmaceuticals+Announces+All+Patients+Cured+of+Babesiosis+After+Tafenoquine+Treatment+in+Expanded+Use+Clinical+Trial/26142599.html Wed, 11 Mar 2026 07:24:00 -0400 A.06822034 A.14320728 O.20026344 O.20250741 O.58280676 SXTP SXTPW http://www.streetinsider.com/Press+Releases/60+Degrees+Pharmaceuticals+Announces+All+Patients+Cured+of+Babesiosis+After+Tafenoquine+Treatment+in+Expanded+Use+Clinical+Trial/26142599.html <ul><li>All three patients enrolled in study have been cured, confirming high cure rate of <strong>tafenoquine</strong> in immunosuppressed patients, as reported by Yale in a 2024 publication</li><li>Company calls for existing babesiosis treatment guidelines to be reviewed in light of the new data</li></ul> <p>WASHINGTON, March 11, 2026 (GLOBE NEWSWIRE) -- <a target="_blank" href="https://www.globenewswire.com/Tracker?data=Xh3W3ckQCJSwUsxtLRhEbKHxgPNlNKSp2QaVxFX-36w4b2c7EqcmudQ7Wtel6waeC2-_XF86mo579UbrGzCwHt8LznYmPsahGyfemenDObigbVN7m9z7OId9maVJUmXDb5Na9ylOd-Y-d8MQLXGeLQ==" rel="nofollow" target="_blank">60 Degrees Pharmaceuticals, Inc.</a> (NASDAQ: SXTP; SXTPW) (“60 Degrees” or the “Company”), a pharmaceutical company focused on developing new medicines for vector-borne disease, today announced that three of three enrolled patients have been cured of babesiosis after completing the<strong> tafenoquine</strong> regimen in the Company’s trial of relapsing http://www.streetinsider.com/Press+Releases/60+Degrees+Pharmaceuticals+Announces+All+Patients+Cured+of+Babesiosis+After+Tafenoquine+Treatment+in+Expanded+Use+Clinical+Trial/26142599.html Wed, 11 Mar 2026 07:24:00 -0400 A.06822034 A.14320728 O.20026344 O.20250741 O.58280676 SXTP SXTPW http://www.streetinsider.com/Globe+Newswire/60+Degrees+Pharmaceuticals+Announces+All+Patients+Cured+of+Babesiosis+After+Tafenoquine+Treatment+in+Expanded+Use+Clinical+Trial/26142599.html <ul><li>All three patients enrolled in study have been cured, confirming high cure rate of <strong>tafenoquine</strong> in immunosuppressed patients, as reported by Yale in a 2024 publication</li><li>Company calls for existing babesiosis treatment guidelines to be reviewed in light of the new data</li></ul> <p>WASHINGTON, March 11, 2026 (GLOBE NEWSWIRE) -- <a target="_blank" href="https://www.globenewswire.com/Tracker?data=Xh3W3ckQCJSwUsxtLRhEbKHxgPNlNKSp2QaVxFX-36w4b2c7EqcmudQ7Wtel6waeC2-_XF86mo579UbrGzCwHt8LznYmPsahGyfemenDObigbVN7m9z7OId9maVJUmXDb5Na9ylOd-Y-d8MQLXGeLQ==" rel="nofollow" target="_blank">60 Degrees Pharmaceuticals, Inc.</a> (NASDAQ: SXTP; SXTPW) (“60 Degrees” or the “Company”), a pharmaceutical company focused on developing new medicines for vector-borne disease, today announced that three of three enrolled patients have been cured of babesiosis after completing the<strong> tafenoquine</strong> regimen in the Company’s trial of relapsing http://www.streetinsider.com/Globe+Newswire/60+Degrees+Pharmaceuticals+Announces+All+Patients+Cured+of+Babesiosis+After+Tafenoquine+Treatment+in+Expanded+Use+Clinical+Trial/26142599.html Wed, 11 Mar 2026 07:24:00 -0400 A.06822034 A.14320728 O.20026344 O.20250741 O.58280676 SXTP SXTPW http://www.streetinsider.com/Globe+Newswire/60+Degrees+Pharmaceuticals+Announces+All+Patients+Cured+of+Babesiosis+After+Tafenoquine+Treatment+in+Expanded+Use+Clinical+Trial/26142599.html <ul><li>All three patients enrolled in study have been cured, confirming high cure rate of <strong>tafenoquine</strong> in immunosuppressed patients, as reported by Yale in a 2024 publication</li><li>Company calls for existing babesiosis treatment guidelines to be reviewed in light of the new data</li></ul> <p>WASHINGTON, March 11, 2026 (GLOBE NEWSWIRE) -- <a target="_blank" href="https://www.globenewswire.com/Tracker?data=Xh3W3ckQCJSwUsxtLRhEbKHxgPNlNKSp2QaVxFX-36w4b2c7EqcmudQ7Wtel6waeC2-_XF86mo579UbrGzCwHt8LznYmPsahGyfemenDObigbVN7m9z7OId9maVJUmXDb5Na9ylOd-Y-d8MQLXGeLQ==" rel="nofollow" target="_blank">60 Degrees Pharmaceuticals, Inc.</a> (NASDAQ: SXTP; SXTPW) (“60 Degrees” or the “Company”), a pharmaceutical company focused on developing new medicines for vector-borne disease, today announced that three of three enrolled patients have been cured of babesiosis after completing the<strong> tafenoquine</strong> regimen in the Company’s trial of relapsing http://www.streetinsider.com/Globe+Newswire/60+Degrees+Pharmaceuticals+Announces+All+Patients+Cured+of+Babesiosis+After+Tafenoquine+Treatment+in+Expanded+Use+Clinical+Trial/26142599.html Wed, 11 Mar 2026 07:24:00 -0400 A.06822034 A.14320728 O.20026344 O.20250741 O.58280676 SXTP SXTPW http://www.streetinsider.com/Globe+Newswire/60+Degrees+Pharmaceuticals+Announces+All+Patients+Cured+of+Babesiosis+After+Tafenoquine+Treatment+in+Expanded+Use+Clinical+Trial/26142599.html <ul><li>All three patients enrolled in study have been cured, confirming high cure rate of <strong>tafenoquine</strong> in immunosuppressed patients, as reported by Yale in a 2024 publication</li><li>Company calls for existing babesiosis treatment guidelines to be reviewed in light of the new data</li></ul> <p>WASHINGTON, March 11, 2026 (GLOBE NEWSWIRE) -- <a target="_blank" href="https://www.globenewswire.com/Tracker?data=Xh3W3ckQCJSwUsxtLRhEbKHxgPNlNKSp2QaVxFX-36w4b2c7EqcmudQ7Wtel6waeC2-_XF86mo579UbrGzCwHt8LznYmPsahGyfemenDObigbVN7m9z7OId9maVJUmXDb5Na9ylOd-Y-d8MQLXGeLQ==" rel="nofollow" target="_blank">60 Degrees Pharmaceuticals, Inc.</a> (NASDAQ: SXTP; SXTPW) (“60 Degrees” or the “Company”), a pharmaceutical company focused on developing new medicines for vector-borne disease, today announced that three of three enrolled patients have been cured of babesiosis after completing the<strong> tafenoquine</strong> regimen in the Company’s trial of relapsing http://www.streetinsider.com/Globe+Newswire/60+Degrees+Pharmaceuticals+Announces+All+Patients+Cured+of+Babesiosis+After+Tafenoquine+Treatment+in+Expanded+Use+Clinical+Trial/26142599.html Wed, 11 Mar 2026 07:24:00 -0400 A.06822034 A.14320728 O.20026344 O.20250741 O.58280676 SXTP SXTPW http://www.streetinsider.com/Globe+Newswire/60+Degrees+Pharmaceuticals+Announces+All+Patients+Cured+of+Babesiosis+After+Tafenoquine+Treatment+in+Expanded+Use+Clinical+Trial/26142599.html <ul><li>All three patients enrolled in study have been cured, confirming high cure rate of <strong>tafenoquine</strong> in immunosuppressed patients, as reported by Yale in a 2024 publication</li><li>Company calls for existing babesiosis treatment guidelines to be reviewed in light of the new data</li></ul> <p>WASHINGTON, March 11, 2026 (GLOBE NEWSWIRE) -- <a target="_blank" href="https://www.globenewswire.com/Tracker?data=Xh3W3ckQCJSwUsxtLRhEbKHxgPNlNKSp2QaVxFX-36w4b2c7EqcmudQ7Wtel6waeC2-_XF86mo579UbrGzCwHt8LznYmPsahGyfemenDObigbVN7m9z7OId9maVJUmXDb5Na9ylOd-Y-d8MQLXGeLQ==" rel="nofollow" target="_blank">60 Degrees Pharmaceuticals, Inc.</a> (NASDAQ: SXTP; SXTPW) (“60 Degrees” or the “Company”), a pharmaceutical company focused on developing new medicines for vector-borne disease, today announced that three of three enrolled patients have been cured of babesiosis after completing the<strong> tafenoquine</strong> regimen in the Company’s trial of relapsing http://www.streetinsider.com/Globe+Newswire/60+Degrees+Pharmaceuticals+Announces+All+Patients+Cured+of+Babesiosis+After+Tafenoquine+Treatment+in+Expanded+Use+Clinical+Trial/26142599.html Wed, 11 Mar 2026 07:24:00 -0400 A.06822034 A.14320728 O.20026344 O.20250741 O.58280676 SXTP SXTPW